Literature DB >> 8163651

Inducible production of nitric oxide in osteoblast-like cells and in fetal mouse bone explants is associated with suppression of osteoclastic bone resorption.

C W Löwik1, P H Nibbering, M van de Ruit, S E Papapoulos.   

Abstract

Nitric oxide (NO) has been suggested to be involved in the regulation of osteoclast activity. Since osteoblasts, through the release of various factors, are the main regulators of osteoclastic resorption, first we have investigated whether osteoblast-like cells and fetal mouse long bone explants are able to produce NO. Second, we have assessed the effect of NO on osteoclastic resorption in whole bone cultures. In this study we show that primary rat osteoblast-like cells as well as the clonal rat osteoblast-like cell line UMR-106, stimulated with IFN-gamma together with TNF-alpha and LPS, produce NO, measured as nitrite production. IL-1 alpha enhanced while TGF-beta 2 inhibited TNF-alpha + IFN-gamma + LPS-stimulated NO production in UMR-106 cells dose dependently. Both the cytokines, however, had no effect when given alone. The competitive inhibitor of NO production, NG-monomethyl-arginine (L-NMMA), and cycloheximide abolished the increase in nitrite production induced by TNF-alpha + IFN-gamma + LPS, while hydrocortisone had no effect, as previously reported for chondrocytes. Calciotropic hormones had either no effect [1,25(OH)2D3] or had a small inhibitory effect (parathyroid hormone) on stimulated NO production. Furthermore, we found that in cultured fetal mouse long bone explants the combination of TNF-alpha + IFN-gamma + LPS as well as the NO donor sodium nitroprusside could inhibit osteoclastic resorption, measured as 45Ca release. The inhibition of resorption was prevented by concurrent administration of L-NMMA. Histological evaluation revealed that the TNF-alpha + IFN-gamma + LPS-induced inhibition of 45Ca release was associated with a decrease in the number of tartrate-resistant acid phosphatase-positive osteoclasts. We propose that the NO production by osteogenic cells (osteoblasts and chondrocytes) may represent an important regulatory mechanism of osteoclastic activity especially under pathological conditions characterized by release of bone-resorbing inflammatory cytokines.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8163651      PMCID: PMC294160          DOI: 10.1172/JCI117124

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  22 in total

1.  Glucocorticoids inhibit the induction of nitric oxide synthase in macrophages.

Authors:  M Di Rosa; M Radomski; R Carnuccio; S Moncada
Journal:  Biochem Biophys Res Commun       Date:  1990-11-15       Impact factor: 3.575

2.  Macrophage deactivating factor and transforming growth factors-beta 1 -beta 2 and -beta 3 inhibit induction of macrophage nitrogen oxide synthesis by IFN-gamma.

Authors:  A Ding; C F Nathan; J Graycar; R Derynck; D J Stuehr; S Srimal
Journal:  J Immunol       Date:  1990-08-01       Impact factor: 5.422

3.  Role of osteoblasts in hormonal control of bone resorption--a hypothesis.

Authors:  G A Rodan; T J Martin
Journal:  Calcif Tissue Int       Date:  1981       Impact factor: 4.333

4.  Osteoclastic inhibition: an action of nitric oxide not mediated by cyclic GMP.

Authors:  I MacIntyre; M Zaidi; A S Alam; H K Datta; B S Moonga; P S Lidbury; M Hecker; J R Vane
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

5.  Induction of nitric oxide synthase in human chondrocytes.

Authors:  R M Palmer; M S Hickery; I G Charles; S Moncada; M T Bayliss
Journal:  Biochem Biophys Res Commun       Date:  1993-05-28       Impact factor: 3.575

6.  Preferential inhibition of cytokine-stimulated bone resorption by recombinant interferon gamma.

Authors:  M Gowen; G E Nedwin; G R Mundy
Journal:  J Bone Miner Res       Date:  1986-10       Impact factor: 6.741

7.  Differentiation kinetics of osteoclasts in the periosteum of embryonic bones in vivo and in vitro.

Authors:  B A Scheven; E W Kawilarang-De Haas; A M Wassenaar; P J Nijweide
Journal:  Anat Rec       Date:  1986-04

8.  Impaired mitogen-induced interferon-gamma production in rheumatoid arthritis and related diseases.

Authors:  T Stolzenburg; H Binz; A Fontana; M Felder; F J Wagenhaeuser
Journal:  Scand J Immunol       Date:  1988-01       Impact factor: 3.487

9.  Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells.

Authors:  D J Stuehr; C F Nathan
Journal:  J Exp Med       Date:  1989-05-01       Impact factor: 14.307

10.  Tetrahydrobiopterin-dependent formation of nitrite and nitrate in murine fibroblasts.

Authors:  G Werner-Felmayer; E R Werner; D Fuchs; A Hausen; G Reibnegger; H Wachter
Journal:  J Exp Med       Date:  1990-12-01       Impact factor: 14.307

View more
  33 in total

Review 1.  Nitric oxide and bone.

Authors:  R J van't Hof; S H Ralston
Journal:  Immunology       Date:  2001-07       Impact factor: 7.397

Review 2.  Mechanisms by which exercise improves bone strength.

Authors:  Charles H Turner; Alexander G Robling
Journal:  J Bone Miner Metab       Date:  2005       Impact factor: 2.626

3.  Nitrate use and changes in bone mineral density: the Canadian Multicentre Osteoporosis Study.

Authors:  S A Jamal; D Goltzman; D A Hanley; A Papaioannou; J C Prior; R G Josse
Journal:  Osteoporos Int       Date:  2008-09-18       Impact factor: 4.507

Review 4.  Molecular aspects of osteoclast function.

Authors:  T J Hall; T J Chambers
Journal:  Inflamm Res       Date:  1996-01       Impact factor: 4.575

5.  iNOS-derived nitric oxide stimulates osteoclast activity and alveolar bone loss in ligature-induced periodontitis in rats.

Authors:  Bruno S Herrera; Rodrigo Martins-Porto; Aline Maia-Dantas; Paula Campi; Luis C Spolidorio; Soraia K P Costa; Thomas E Van Dyke; Robert Gyurko; Marcelo N Muscara
Journal:  J Periodontol       Date:  2011-03-21       Impact factor: 6.993

Review 6.  Antihypertensive medications, bone mineral density, and fractures: a review of old cardiac drugs that provides new insights into osteoporosis.

Authors:  Mahua Ghosh; Sumit R Majumdar
Journal:  Endocrine       Date:  2014-02-07       Impact factor: 3.633

Review 7.  Nitric oxide donors for the treatment of osteoporosis.

Authors:  Sophie A Jamal; Celeste J Hamilton
Journal:  Curr Osteoporos Rep       Date:  2012-03       Impact factor: 5.096

Review 8.  Nitric oxide signaling in mechanical adaptation of bone.

Authors:  J Klein-Nulend; R F M van Oers; A D Bakker; R G Bacabac
Journal:  Osteoporos Int       Date:  2013-12-10       Impact factor: 4.507

9.  Interleukin 17 synergises with tumour necrosis factor alpha to induce cartilage destruction in vitro.

Authors:  R L Van Bezooijen; L Van Der Wee-Pals; S E Papapoulos; C W G M Löwik
Journal:  Ann Rheum Dis       Date:  2002-10       Impact factor: 19.103

10.  Organic nitrates for osteoporosis: an update.

Authors:  Celeste J Hamilton; Lauren S Reid; Sophie A Jamal
Journal:  Bonekey Rep       Date:  2013-02-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.